This is a retrospective observational cohort study using healthcare administrative claims data from the USA.~This study will use anonymized patient claims data from PRA's Symphony Health Patient Source Integrated Dataverse (IDV) database. Data are routinely collected in healthcare encounters from all available healthcare sites (inpatient hospital, outpatient hospital, physician office, pharmacy, etc.) for all types of provided services including specialty, preventive care, and office-based treatments.~The patients for inclusion in the study analyses will be identified based on the prescribed anabolic therapy filled (ABL or TPTD). The study intake period was chosen to coincide with the date of the FDA approval of ABL in the USA.~This study will use anonymized patient claims data from the Symphony Health Patient Source IDV database including the enhanced hospital data.~This retrospective cohort study is expected to include a total of 16,000 patients; 8000 patients per treatment cohort (ABL or TPTD).
The purpose of the current study is to evaluate the real-world comparative effectiveness and cardiovascular safety of ABL compared with TPTD during the 18 month period after treatment initiation in propensity score (PS)-matched cohorts